Can eltrombopag (Revlan) cure patients with thrombocytopenia?

Eltrombopag is an oral small molecule thrombopoietic agonist (TPO-RA), mainly used to treat chronic immune thrombocytopenia (ITP), aplastic anemia and chronic hepatitis C-related thrombocytopenia. It activates the thrombopoietin receptor (TPO-R) to promote the maturation of megakaryocytes and platelet production in the bone marrow, thereby effectively increasing the patient's platelet level. Clinically, eltrombopag has significant performance in improving the risk of bleeding and increasing platelet count, but whether it can "cure" thrombocytopenia needs to be distinguished based on the nature of the disease and the mechanism of drug action.

Eltrombopag does not fundamentally cure immune thrombocytopenia (ITP). The drug works by promoting platelet production rather than directly eliminating the immune response that causes platelet destruction. In other words, it is more of a "symptomatic treatment" than a "causal treatment." After stopping the drug, the platelet count of some patients may gradually drop to the original level, or even cause bleeding again. However, after long-term stable medication, the immune system of some patients can gradually return to balance, and platelets can still be maintained within a safe range after discontinuation of medication. This is called "drug-induced sustained remission," but the proportion is low, accounting for only about 10% to 20% of the patient population.

Based on clinical research and practical experience, eltrombopag has significant efficacy and high safety. Most patients can observe an increase in platelet count within 1~2 weeks after taking the drug, and about 70% of patients can achieve an effective response. For long-term users, platelet levels, liver function, and risk of blood clots need to be monitored regularly, as high platelet levels may increase the likelihood of blood clots forming. For children or elderly patients, the dosage should be adjusted strictly under the guidance of a doctor. Even if not curable, eltrombopag can significantly reduce bleeding events, improve quality of life, and prolong complication-free survival.

The therapeutic goals of eltrombopag are more to maintain platelet stability and long-term disease control. For refractory diseases such as chronic ITP, it provides patients with a safe, effective and long-term oral management solution. Doctors usually gradually adjust the dose based on the patient's response, trying to maintain stable platelet levels at low doses to reduce the risk of side effects. Overall, eltrombopag is not a "curative" drug, but it has important clinical significance in disease control, improving prognosis, and reducing hormone dependence. For patients who hope to achieve remission after drug withdrawal, long-term monitoring and individualized treatment under the guidance of a doctor, combined with immune regulation and lifestyle management, are required to achieve more ideal long-term effects.

Reference materials:https://www.drugs.com/